Somatogen (SMTG) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: borb who wrote (390)	2/21/1998 9:16:00 PM
From: R. M. Rosenthal	Read Replies (1) of 442

Below is a post from a new site that purports to seriously specialize in excellent short candidates. Given the company/product cited (BTIM), I thought some of our SMTG experts might be interested. Is BTIM overinflating market prospects for it's blood product? There appear to be other questionable goings on in BTIM history... Perhaps this is an opportunity for us to reap some more immediate profits while SMTG pumps slowly ahead. Thanks for all input. (BTIM closed fri. 16 1/8) RMR >>BTIM: Currently 17 - price target < 1 Biotime is supposedly a development stage biotech company. Their lead product candidate is called Hextend. Basically it is used as a blood volume extender during procedures such as high blood-loss surgery. Problem is that this market is pretty much covered by commodities such as saline solution and products such as Hespan. At most..a $50 million market. Hextend's chances (even after FDA approval) of significantlly penetrating this market are slim to none...and slim is out of town. Biotime believers make the Zitel zealots look like Quakers by comparison. They believe that Biotime's market is far, far, far bigger...and Hextend has magical properties which make it BETTER than Hespan. Guess what? They're wrong!!<<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next